MADRID Spain, 28 Sept - 2 Oct
We’ve recently concluded another successful event at ERS 2019, where GSK marked 50 years of respiratory excellence and celebrated this milestone with you and other international experts. At the event, GSK also shared exciting new data across asthma, COPD and severe asthma. We have distilled down some of the highlights from the event and are delighted to share them in our newsletter and through expert videos with you.
Read the summary of ERS highlights here

ERS 2019 Day 3 Highlights

Lunchtime Session: Inhaler technology (A joint ERS/Industry session)

ERS 2019 Day 2 Highlights

Hot Topics: New recommendations and priorities for asthma management (A joint GINA/ERS update on asthma)

State of the Art Session: Airway disease (Update on clinical studies)

ERS 2019 Day 1 Highlights

Lunchtime session: An update on COPD (A joint ERS/NEJM session)

Guidelines Session: Severe asthma guidelines (Update on 2019 ERS/ATS guidelines)

Adverse events should be reported. For reporting of adverse events, please write to

If you have any questions or comments, please contact us.
About your privacy: your privacy is important to us. To find out more, please read our privacy policy.
You can also view our website terms of use.

Anoro Ellipta, Incruse Ellipta, Relvar Ellipta and Trelegy Ellipta were developed in collaboration with Inc.

©2019 GSK Group of Companies. All rights reserved.
Trademarks are owned by or licensed to the GSK group of companies.
GlaxoSmithKline Pte Ltd, 23 Rochester Park, Singapore 139234, registered in Singapore No. 198102938K

Date of preparation: October 2019